The U.S. patent system feels to me an awful lot like the Titanic right now. The Trump Administration is withdrawing employment offers to patent examiners and firing examiners still within their ...

As 2025 unfolds, changes across the patent landscape are unfolding. From agency leadership transitions to proposed legislation and evolving ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.

According to a recent market analysis, startups with patents and trademarks are 10 ... costs and accelerate timelines. HBR’s analysis particularly notes how important the latter is, as not ...

As pharmaceutical companies continue to innovate at a rapid pace, intellectual property policies will remain central to discussions about global health equity.

And, oddly enough, NJOY is in the middle of patent litigation with Juul ... But look at the timeline of strategic moves Altria has made to deal with this issue. It spun off its foreign business ...

Harmony Biosciences Holdings Inc (HRMY) reports robust financial performance and strategic progress, despite facing ...

LIST wins contract to conduct feasibility study on enriching uranium to empower Department of the Air Force’s global operations Oak Ridge, ...